Navigation Links
Rigel Provides Pipeline Update
Date:10/24/2013

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced updates on two of the Company's pipeline products: R333, a topical dermatological JAK/SYK inhibitor, and fostamatinib, an oral SYK inhibitor.  

R333 Update
Rigel announced that R333, which was being evaluated as a potential therapeutic for active skin lesions in patients with discoid lupus erythematosus (DLE), did not meet the primary endpoint in a recently completed Phase 2 clinical study.  The primary endpoint was the proportion of patients who achieved at least a 50% decrease from baseline in the total combined Erythema and Scaling score of all treated lesions at Week 4.  R333 was shown to be relatively safe and well tolerated.  In light of these overall findings, Rigel has decided not to pursue this indication further with R333. 

Fostamatinib Update
Rigel representatives met with the FDA for an end-of-Phase 2 meeting for fostamatinib, an oral SYK inhibitor in development for patients with immune thrombocytopenic purpura (ITP).  Rigel expects to initiate two pivotal Phase 3 studies in the first half of 2014.  Each of these trials are expected to enroll approximately 75 patients who would be treated for six months and have the option to enroll in an extension study.  These trials will be randomized, placebo-controlled and will enroll verified ITP patients with platelet counts below 30,000 platelets per microliter of blood.   The goal of the trials will be to achieve a durable platelet count increase to over 50,000 platelets per microliter of blood.  Rigel expects top line data from these studies in 2015.

"These events provide clarity to Rigel's pipeline. We now have a clear picture of the Phase 3 program for fostamatinib in ITP and we p
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rigel to Present at Stifel Healthcare Conference
2. Rigel To Focus On ITP, DLE And Dry Eye
3. Rigels R343 Did Not Meet Primary Endpoint in Asthma Study
4. Rigel Announces Second Quarter 2013 Financial Results
5. Rigel Will Resume Responsibility for Fostamatinib Program
6. Rigels R348 to Initiate Phase 2 Clinical Trial in Dry Eye
7. Rigel Announces First Quarter 2013 Financial Results
8. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
9. Rigel Announces Participation at Two Investor Conferences
10. Rigel to Present at BIO CEO & Investor Conference
11. Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , Indien, July 23, 2014 /PRNewswire/ ... additional scope für Arbeiten für Sadara Chemical ... comprehensive Engineering Information System innerhalb des integrierten ... Dieser award of additional scope im Wert ... des zuvor abgeschlossenen Vertrags dar, dessen Wert ...
(Date:7/22/2014)... July 23, 2014   - Investment ... Pharmaceutical Co., Ltd. (hereinafter "Taiho"), a fully-fledged oncology pharmaceutical ... be investing US$30 million in Remiges BioPharma Fund (hereinafter ... Taiho has a long history of developing ... and cancer patients. Our development of TAS-102 is an ...
(Date:7/22/2014)... , July 22, 2014  Nektar Therapeutics (Nasdaq: ... second quarter ended June 30, 2014 on Thursday, July 31, ... Robin , president and chief executive officer, will host a ... Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... conference call can be accessed through a link that is ...
Breaking Medicine Technology:Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 2Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 3Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 4Taiho Pharmaceutical Invests US$30 Million in Remiges BioPharma Fund, LP 2Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets 3
... Healthcare announced today that it has acquired Alpha Care ... health economics and policy solutions for pharmaceutical, medical device, ... will expand its health economics, pricing and market access ... office in Berlin, Germany, will allow Boston Healthcare to ...
... being released by the U.S. Food and Drug Administration: ... Fast Facts FDA ... to feed SimplyThick, a thickening agent for management of ... The product may cause necrotizing enterocolitis (NEC), a life-threatening ...
Cached Medicine Technology:Boston Healthcare Acquires Alpha Care GmbH, Expanding Health Economics, Pricing and Reimbursement Consulting Presence in Europe 2FDA: Do Not Feed SimplyThick to Premature Infants 2FDA: Do Not Feed SimplyThick to Premature Infants 3
(Date:7/23/2014)... 2014 QueenBeeTickets.com is reducing the prices of ... for rock music fans who are still in the process ... the site, they can use promo code “DISCOUNT” to get ... to view the inventory of discounted tickets at QueenBeeTickets.com. , ... September and October, with The Eagles concert tickets literally disappearing ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 TeraGanix ... in Casa Grande, Arizona, located only 4.5 miles off of ... increase the convenience and accessibility for businesses in the Arizona ... and growing crops. , Its Casa Grande location is only ... less than one hour from Phoenix. With over 26 ...
(Date:7/23/2014)... Il (PRWEB) July 23, 2014 ISI ... solutions, has released Infortel Speech Analytics, a ... solutions. , Infortel Speech Analytics gives users the ability ... and/or video recordings , as well as chat ... this solution may not be new, adding speech analytics ...
(Date:7/23/2014)... There is inherently nothing wrong with sweating. ... healthy enough to react to specific changes in the ... toxins and bacteria from the body in ways that ... do. , However, the social implications for people ... “excessive sweating”—are serious: since sweating itself often causes instances ...
(Date:7/23/2014)... 2014 According to the latest market ... throughout the region, the Northern Virginia real estate ... are selling quickly throughout the area, and median sale ... The Northern Virginia market includes the city of Alexandria, ... The Northern Virginia region saw median sale prices increase ...
Breaking Medicine News(10 mins):Health News:History of The Eagles Tour Tickets: QueenBeeTickets.com Reduces Prices on Remaining Inventory of Concert Tickets for 2014 Shows 2Health News:TeraGanix Opens New Arizona-Based Agricultural Products Supply Facility 2Health News:TeraGanix Opens New Arizona-Based Agricultural Products Supply Facility 3Health News:ISI Telemanagement Solutions, Inc. Releases Infortel® Speech Analytics 2Health News:ISI Telemanagement Solutions, Inc. Releases Infortel® Speech Analytics 3Health News:Beat Your Sweating Demons Review | The Problem With Excessive Sweating and Solving it Naturally – Vinamy.com 2Health News:Beat Your Sweating Demons Review | The Problem With Excessive Sweating and Solving it Naturally – Vinamy.com 3Health News:Northern Virginia Real Estate Company Pasquali Realty Group Announces Median Sale Price Increased in the Region in June 2014 2
... cancer may also mean surviving pain, according to a study ... of cancer survivors at least two years post diagnosis have ... ahead of print in the American Cancer Society,s journal ... among the growing number of U.S. cancer survivors. ...
... Jan. 13 (HealthDay News) -- This winter will not be a ... to be a more typical flu season, experts say. And ... shot, advice that seniors in particular should heed since the prevalent ... hardest, the experts added. The H1N1 flu virus tended to strike ...
... data from counties across the United States led to the ... risk factor for suicide, according to a provocative study published ... Biology , a peer-reviewed journal published by Mary Ann Liebert, ... Brenner, MD, PhD, and David Cheng, MD, University Hospitals Case ...
... receive more information about the pitfalls of breast cancer screening, ... false-positive results faced serious anxiety and reduced quality of life ... online by BJS, the British Journal of Surgery , ... is abnormal but no cancer is present - had to ...
... COLUMBUS, Ohio New research shows that oncolytic viruses, ... more effective in treating deadly brain tumors if equipped ... The enzyme, called chondroitinase, helps the cancer-killing virus clear ... fill space between cells and impede the virus,s movement ...
... the Kimmel Cancer Center at Jefferson and two other ... protein SIRT1, known for its life-spanning effects in different ... to prostate cancer, prostatic intraepithelial neoplasia (PIN). ... cancer prevention drugs that could not only block prostate ...
Cached Medicine News:Health News:Cancer survivors likely to experience pain at some point in care: U-M study shows 2Health News:Flu Season Looks Normal This Year, Experts Say 2Health News:Women with false-positive mammograms report high anxiety and reduced quality of life 2Health News:Women with false-positive mammograms report high anxiety and reduced quality of life 3Health News:Virus might fight brain tumors better if armed with bacterial enzyme, study shows 2Health News:'Longevity' protein SIRT1 may ward off precursor to prostate cancer 2
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
Vertical punch designed to create a 1.5mm clean cylindrical hole. Rotatable for convenient positioning. Flat Handle. Overall length 87mm....
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
Medicine Products: